文献速递甲状腺疾病

左甲状腺素、干燥甲状腺提取物及左甲状腺素+碘塞罗宁治疗甲状腺功能减退症的疗效比较

Comparative Effectiveness of Levothyroxine, Desiccated Thyroid Extract, and Levothyroxine+Liothyronine in Hypothyroidism.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

这项前瞻性随机双盲交叉研究纳入75例甲减患者,随机接受LT4、LT4+LT3或DTE治疗22周。整体而言,三种治疗在主要和次要结局上无差异;但LT4治疗下症状最明显的1/3患者更偏好含T3治疗,并在症状问卷、生活质量、抑郁和视觉记忆方面有改善。

要点

  • 整体甲减患者中,LT4、LT4+LT3和DTE的疗效相似。
  • LT4治疗下症状最重的1/3患者更偏好含T3治疗并获改善。
  • DTE组心率有轻度增加,其余生化指标无差异。

核心结论

  • 整体而言,接受DTE、LT4+LT3或LT4治疗的甲减患者结局相似。
  • 在LT4治疗下症状最明显的患者更偏好LT4+LT3或DTE治疗,并对此有积极反应。

研究设计与样本

  • 前瞻性、随机、双盲、交叉研究,纳入75例甲减患者,随机分配至LT4、LT4+LT3或DTE治疗22周。
  • 主要结局为TSQ-36、GHQ-12、VMS-IV和BDI评分;采用线性混合模型分析,受试者为随机因子,组别为固定效应。

主要发现

  • 所有治疗组血清TSH均保持在参考范围内。
  • 除DTE引起心率轻度增加外,主要和次要结局均无差异。
  • 治疗偏好无差异,甲减病因或Thr92Ala-DIO2基因多态性未干扰结局。
  • 对LT4治疗下症状最明显的1/3患者进行亚组分析,显示强烈偏好含T3治疗,并在TSQ-36、GHQ-12、BDI和视觉记忆指数(VMS-IV组分)上表现改善。

临床怎么用

  • 对于LT4治疗下症状明显的甲减患者,可考虑换用LT4+LT3或DTE治疗。
  • 整体甲减人群中选择LT4、LT4+LT3或DTE时,疗效相似,需结合患者偏好和临床情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Studies comparing levothyroxine (LT4) therapy with LT4 + liothyronine (LT3) or desiccated thyroid extract (DTE) did not detect consistent superiority of either treatment. Here, we investigated these therapies, focusing on the whole group of LT4-treated hypothyroid patients, while also exploring the most symptomatic patients. METHODOLOGY: Prospective, randomized, double-blind, crossover study of 75 hypothyroid patients randomly allocated to 1 of 3 treatment arms, LT4, LT4 + LT3, and DTE, for 22 weeks. The primary outcomes were posttreatment scores on the 36-point thyroid symptom questionnaire (TSQ-36), 12-point quality of life general health questionnaire (GHQ-12), the Wechsler memory scale-version IV (VMS-IV), and the Beck Depression Inventory (BDI). Secondary endpoints included treatment preference, biochemical and metabolic parameters, etiology of hypothyroidism, and Thr92Ala-DIO2 gene polymorphism. Analyses were performed with a linear mixed model using subject as a random factor and group as a fixed effect. RESULTS: Serum TSH remained within reference range across all treatment arms. There were no differences for primary and secondary outcomes, except for a minor increase in heart rate caused by DTE. Treatment preference was not different and there were no interferences of the etiology of hypothyroidism or Thr92Ala-DIO2 gene polymorphism in the outcomes. Subgroup analyses of the 1/3 most symptomatic patients on LT4 revealed strong preference for treatment containing T3, which improved performance on TSQ-36, GHQ-12, BDI, and visual memory index (VMS-IV component). CONCLUSIONS: As a group, outcomes were similar among hypothyroid patients taking DTE vs LT4 + T3 vs LT4. However, those patients that were most symptomatic on LT4 preferred and responded positively to therapy with LT4 + LT3 or DTE.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Shakir MKM, Brooks DI, McAninch EA, et al. Comparative Effectiveness of Levothyroxine, Desiccated Thyroid Extract, and Levothyroxine+Liothyronine in Hypothyroidism. J Clin Endocrinol Metab. 2021. PMID: 34185829. doi:10.1210/clinem/dgab478

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。